Tuberc Respir Dis.
2024 Apr;87(2):206-208. 10.4046/trd.2023.0188.
Treatment Outcomes of Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid
- Affiliations
-
- 1Department of Clinical and Community Pharmacy, Study Program of Pharmacy, Faculty of Medicine, Hang Tuah University, Surabaya, Indonesia
- 2Pre-Clinical and Clinical Studies, National Research and Innovation Agency, Central Jakarta, Indonesia
- KMID: 2553781
- DOI: http://doi.org/10.4046/trd.2023.0188
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Concurrent, Prolonged Use of Bedaquiline and Delamanid for Multidrug-Resistant Tuberculosis
- Treatment Outcomes of Fluoroquinolone- Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid - Authors’ Reply
- Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
- Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
- Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
